Hutchmed (China) Limited HUTCHMED to Announce 2023 Final Results
February 01 2024 - 2:30AM
RNS Regulatory News
RNS Number : 6811B
Hutchmed (China) Limited
01 February 2024
HUTCHMED to Announce 2023 Final Results
Hong Kong, Shanghai
& Florham Park, NJ - Thursday, February 1, 2024:
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM;
SEHK:13) will be announcing its final results for the year ended
December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am
Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) /
7:30 pm Hong Kong Time (HKT).
Analysts and investors are invited to join a
conference call and audio webcast presentation with Q&A,
conducted by HUTCHMED management.
The English conference call and audio webcast will
take place at 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on
Wednesday, February 28, 2024. In addition to the usual
English webcast, there will also be a Chinese (Putonghua) webcast
at 7:30 pm EST / 12:30 am GMT / 8:30 am HKT on Thursday, February
29, 2024. Both webcasts will be available live via the
company website at www.hutch-med.com/event/.
The presentation will be available for downloading before the
conference call begins. Details of the conference call
dial-in will be provided in the financial results
announcement and on the company website. A replay will
also be available on the website shortly after the
event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13)
is an innovative, commercial-stage, biopharmaceutical company. It
is committed to the discovery and global development and
commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. It has
approximately 5,000 personnel across all its companies, at the
center of which is a team of about 1,800 in oncology/immunology.
Since inception it has focused on bringing cancer drug candidates
from in-house discovery to patients around the world, with its
first three medicines marketed in China, the first of which is also marketed in the U.S. For more
information, please visit:
www.hutch‑med.com
or follow us on LinkedIn.
CONTACTS
Investor Enquiries
|
+852 2121 8200 /
ir@hutch-med.com
|
|
|
Media Enquiries
|
|
Ben Atwell / Alex Shaw,
FTI Consulting
|
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) /
HUTCHMED@fticonsulting.com
|
Zhou Yi, Brunswick
|
+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
|
|
|
Nominated Advisor
|
|
Atholl Tweedie / Freddy Crossley /
Daphne Zhang, Panmure Gordon
|
+44 20 7886 2500
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORKZGGZNMZGDZG
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024